Omega 3 clinical brief
Omega 3
Dossier liveACardiovascular
Evidence strength
High confidence
307 meta-analyses - 407 RCTs - 925 tracked studies
What it is for
Hypertriglyceridemia (TG 200-499 mg/dL) - standard therapy
The clearest current human use case based on dose, outcomes, and clinical coverage.
What moves
Highest-signal biomarkers
Human linked
HOMA-IR
Glycemic control
Decrease
Grade A
HbA1c
Glycemic control
No Effect
Grade A
Fasting glucose
Glycemic control
Decrease
Grade B
Top caution
Drug interaction
High-dose EPA >=4g/day (IPE) associated with increased AF risk in REDUCE-IT (HR 1.69, p<0.001) and STRENGTH trials; mechanism unclear - possible membrane fluidity effects on atrial L-type calcium channels or left atrial structural remodeling; concurrent AF-risk drugs compound arrhythmia likelihood
Evidence index
89
Authored product-registry confidence score
Meta-analyses
307
Pooled human evidence
RCTs
407
Randomized clinical trials
Tracked studies
925
Studies currently mapped to this dossier
Executive summary
Immediate brief
Omega 3 is a Cardiovascular with its clearest current use in Hypertriglyceridemia (TG 200-499 mg/dL) - standard therapy.
High confidence human evidence supports the brief, anchored by 925 tracked studies, 307 meta-analyses, 407 RCTs and the most reliable movement in HOMA-IR, HbA1c, Fasting glucose.
Grade A: fishy taste, eructation, diarrhea, nausea are most common AEs. High-dose EPA >=4g/day (IPE) associated with increased AF risk in REDUCE-IT (HR 1.69, p<0.001) and STRENGTH trials; mechanism unclear - possible membrane fluidity effects on atrial L-type calcium channels or left atrial structural remodeling; concurrent AF-risk drugs compound arrhythmia likelihood Effect is measure-dependent and likely reflects HOMA-IR limitations (insulin secretion × insulin resistance conflated) rather than true IS improvement; clinical relevance uncertain
Anchor decision
Hypertriglyceridemia (TG 200-499 mg/dL) - standard therapy
Best current human use case
Confidence
High confidence
307 meta-analyses - 407 RCTs - 925 tracked studies
Read next
Drug interaction
Pressure-test the lead caution before acting.
Reading guide
How to use this brief
1. Orient
Use the overview tab to understand mechanism, safety, scope, and where the current evidence still has blind spots.
2. Pressure-test
Move into evidence and biomarkers once the memo already makes sense, so the tables confirm or challenge the narrative rather than replace it.
3. Operationalize
Finish with dosing and PGx when the compound still looks useful and you are deciding whether it belongs in a real protocol.
Major warning
XPregnancy - high-dose EPA supplementation (>=3 g/day)
Protocol formulation selection (EPA-rich vs DHA-rich) should be matched to target cognitive outcome domain
Overview
Clinical posture
Start with mechanism and safety, then move into scope, synergies, and the open questions that still matter before going deeper into tables.
Primary signal
Mechanism summary
Read this as the shortest defensible explanation for why the compound belongs in the conversation at all.
Co-primary
Safety summary
These are the reasons this compound can still break trust if the protocol fit is otherwise attractive.
Supporting context
Evidence scope
Read these caveats before assuming the effect sizes generalize cleanly across every population or use case.
Evidence scope
ReviewEffect is measure-dependent and likely reflects HOMA-IR limitations (insulin secretion × insulin resistance conflated) rather than true IS improvement; clinical relevance uncertain
Evidence scope
ReviewFormulation matters critically; DHA co-administration may offset CV benefit of TG lowering; EPA-only preferred for CV risk reduction
Evidence scope
ReviewEPA dose is the active variable; for ADHD, high-EPA formulations required; DHA-only or equal-ratio products likely ineffective
Generalizability
ReviewGlycemic effects of omega-3 are pharmacogenomically modulated; population-average null findings may mask benefit in specific genotypes
Synergies
Potential pairing logic is useful only when it adds a cleaner decision path, not when it becomes an excuse to stack indiscriminately.
No validated pairing data yet
No dossier-backed pairing evidence is currently mapped for Omega 3.
Research unknowns
These are the open questions that still keep the compound from reading like a closed case.